Updates are available Correction dated 2022-04-25
Click to view Correction: https://doi.org/10.1186/s40478-022-01367-y
-
Authors
Campion, Lindsey N.
Mejia Maza, Alan
Yadav, Rachita
Penney, Ellen B.
Murcar, Micaela G.
Correia, Kevin
Gillis, Tammy
Fernandez-Cerado, Cara
Velasco-Andrada, M. Salvie
Legarda, G. Paul
Ganza-Bautista, Niecy G.
Lagarde, J. Benedict B.
Acuña, Patrick J.
Multhaupt-Buell, Trisha
Aldykiewicz, Gabrielle
Supnet, Melanie L.
De Guzman, Jan K.
Go, Criscely
Sharma, Nutan
Munoz, Edwin L.
Ang, Mark C.
Diesta, Cid Czarina E.
Bragg, D. Cristopher
Ozelius, Laurie J. http://orcid.org/0000-0002-7820-1684
Wheeler, Vanessa C.
-
Funding
Funding for this research was provided by:
COLLABORATIVE CENTER FOR XDP
Massachusetts General Hospital
- License Information
-
More Information
Article History
Received: 21 January 2022
Accepted: 14 March 2022
First Online: 8 April 2022
Change Date: 25 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40478-022-01367-y
Declarations
:
: All participants provided written informed consent, and the study was approved by Massachusetts General Hospital (Boston, MA, USA) and Jose R. Reyes Memorial Medical Center (Manila, Philippines) Institutional Review Boards (IRBs). Post-mortem brain tissue from XDP patients was obtained in collaboration with the Collaborative Center for XDP (CCXDP), at Massachusetts General Hospital (Boston, MA, USA), Makati Medical Center (Makati City, Philippines), and the Sunshine Care Foundation (Panay, Philippines). All procedures related to the collection, processing, and use of XDP patient post-mortem brain tissues were approved by IRBs at Makati Medical Center (Makati City, Philippines) and Massachusetts General Hospital (Boston, MA, USA).
: All authors consented to the publication of the manuscript.
: V.C.W. is a scientific advisory board member of Triplet Therapeutics, Inc., a company developing new therapeutic approaches to address triplet repeat disorders such Huntington’s disease and Myotonic Dystrophy. Her financial interests in Triplet Therapeutics were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. She is a scientific advisory board member of LoQus23 Therapeutics, Ltd and has provided paid consulting services to Alnylam, Inc., Acadia Pharmaceuticals and Biogen, Inc. She has also received research support from Pfizer Inc. L.J.O. receives royalties from Athena Diagnostics.
